Hydrophobic binary mixtures containing amphotericin B as lipophilic solutions for the treatment of cutaneous leishmaniasis

被引:0
|
作者
Augis, Luc [1 ]
Nguyen, Canh Hung [1 ,2 ]
Ciseran, Cecile [1 ]
Wacha, Andras [3 ]
Nome, Francoise Mercier [4 ,5 ]
Domenichini, Severine [4 ]
Sizun, Christina [6 ]
Fourmentin, Sophie [7 ]
Legrand, Francois-Xavier [1 ]
机构
[1] Univ Paris Saclay, Inst Galien Paris Saclay, CNRS, F-91400 Orsay, France
[2] Hanoi Univ Pharm, Dept Pharmaceut, 13-15 Thanh Tong, Hanoi, Vietnam
[3] Inst Mat & Environm Chem, Res Ctr Nat Sci, Magyar Tudosok Korutja 2, H-1117 Budapest, Hungary
[4] Univ Paris Saclay, Ingn & Plateformes Serv Innovat Therapeut, Inserm, CNRS, F-91400 Orsay, France
[5] Univ Paris Saclay, Inserm, Inflammat Microbiome & Immunosurveillance, F-91400 Orsay, France
[6] Univ Paris Saclay, Inst Chim Subst Nat, CNRS, UPR 2301, F-91198 Gif Sur Yvette, France
[7] Univ Littoral Cote dOpale, Unite Chim Environm & Interact Vivant, UR 4492, UCEIV, F-59140 Dunkerque, France
关键词
Cutaneous leishmaniasis; Amphotericin B; Deep eutectic solvents; Low transition temperature mixtures; Lipophilic solution; MTT assay; Franz diffusion cells; DEEP EUTECTIC SOLVENTS; IONIC LIQUIDS; CHOLINE CHLORIDE; INTERMOLECULAR INTERACTIONS; CARBOXYLIC-ACIDS; MICROEXTRACTION; EXTRACTION; PHASE; GREEN; PHOSPHONIUM;
D O I
10.1016/j.ijpharm.2024.124486
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cutaneous leishmaniasis, caused by Leishmania parasites, requires treatments with fewer side effects than those currently available. The development of a topical solution based on amphotericin B (AmB) was pursued. The considerable interest in deep eutectic solvents (DESs) and their remarkable advantages inspired the search for a suitable hydrophobic excipient. Various mixtures based on commonly used hydrogen bond donors (HBDs) and acceptors (HBAs) for DES preparations were explored. Initial physical and in-vitro screenings showed the potential of quaternary phosphonium salt-based mixtures. Through thermal analysis, it was determined that most of these mixtures did not exhibit eutectic behavior. X-ray scattering studies revealed a sponge-like nanoscale structure. The most promising formulation, based on a combination of trihexyl(tetradecyl)phosphonium chloride and 1-oleoyl-rac-glycerol, showed no deleterious effects through histological evaluation. AmB was fully solubilized at concentrations between 0.5 and 0.8 mg & sdot;mL- 1, depending on the formulation. The monomeric state of AmB was observed by circular dichroism. In-vitro irritation tests demonstrated acceptable viability for AmBbased formulations up to 0.5 mg & sdot;mL- 1. Additionally, an ex-vivo penetration study on pig ear skin revealed no transcutaneous passage, confirming AmB retention in healthy, unaffected skin.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Two cases of successful treatment of multilesional cutaneous leishmaniasis with liposomal amphotericin B
    Butsch, Florian
    Faulde, Michael
    Debus, Andrea
    Bogdan, Christian
    von Stebut, Esther
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 (01): : 83 - 85
  • [22] Efficacious topical treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B
    Vardy, D
    Barenholz, Y
    Naftoliev, N
    Klaus, S
    Gilead, L
    Frankenburg, S
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2001, 95 (02) : 184 - 186
  • [23] In Vitro Efficacy and Toxicity Assessment of an Amphotericin B Gel for the Treatment of Cutaneous Leishmaniasis
    Sosa, Lilian
    Espinoza, Lupe Carolina
    Silva-Abreu, Marcelle
    Jaramillo-Fierro, Ximena
    Berenguer, Diana
    Riera, Cristina
    Rincon, Maria
    Calpena, Ana C.
    PHARMACEUTICALS, 2025, 18 (03)
  • [24] Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B
    Frankenburg, S
    Glick, D
    Klaus, S
    Barenholz, Y
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (12) : 3092 - 3096
  • [25] A topical gel nanoformulation of amphotericin B (AmB) for the treatment of cutaneous leishmaniasis (CL)
    Reza Boshrouyeh
    Samar Amari
    Mohammad Boshrouyeh Ghandashtani
    Seyed Ebrahim Alavi
    Hasan Ebrahimi Shahmabadi
    Journal of Sol-Gel Science and Technology, 2023, 105 : 768 - 780
  • [26] A topical gel nanoformulation of amphotericin B (AmB) for the treatment of cutaneous leishmaniasis (CL)
    Boshrouyeh, Reza
    Amari, Samar
    Ghandashtani, Mohammad Boshrouyeh
    Alavi, Seyed Ebrahim
    Shahmabadi, Hasan Ebrahimi
    JOURNAL OF SOL-GEL SCIENCE AND TECHNOLOGY, 2023, 105 (03) : 768 - 780
  • [27] TREATMENT OF EXPERIMENTAL CUTANEOUS LEISHMANIASIS WITH LIPOSOME-INTERCALATED AMPHOTERICIN-B
    PANOSIAN, CB
    BARZA, M
    SZOKA, F
    WYLER, DJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 25 (05) : 655 - 656
  • [28] Diffuse (anergic) cutaneous leishmaniasis responding to amphotericin B
    Morrison, B.
    Mendoza, I.
    Delgado, D.
    Reyes Jaimes, O.
    Aranzazu, N.
    Paniz Mondolfi, A. E.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2010, 35 (04) : e116 - e119
  • [29] Cholesterol improves stability of amphotericin B nanoemulsion: promising use in the treatment of cutaneous leishmaniasis
    Mansur-Alves, Izabela
    Furtado Lima, Brenda Lorrayne
    Santos, Thais Tunes
    Araujo, Naialy F.
    Frezard, Frederic
    Islam, Arshad
    de Barros, Andre L. B.
    dos Santos, Delia C. M.
    Fernandes, Christian
    Ferreira, Lucas A. M.
    Aguiar, Marta M. G.
    NANOMEDICINE, 2022, 17 (18) : 1237 - 1251
  • [30] Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: A literature review
    Mosimann, Vincent
    Neumayr, Andreas
    Paris, Daniel H.
    Blum, Johannes
    ACTA TROPICA, 2018, 182 : 246 - 250